Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
92 tokens/sec
Gemini 2.5 Pro Premium
50 tokens/sec
GPT-5 Medium
22 tokens/sec
GPT-5 High Premium
21 tokens/sec
GPT-4o
97 tokens/sec
DeepSeek R1 via Azure Premium
87 tokens/sec
GPT OSS 120B via Groq Premium
459 tokens/sec
Kimi K2 via Groq Premium
230 tokens/sec
2000 character limit reached

Blinded and unblinded sample size re-estimation in crossover trials balanced for period (1803.10130v1)

Published 27 Mar 2018 in stat.ME

Abstract: The determination of the sample size required by a crossover trial typically depends on the specification of one or more variance components. Uncertainty about the value of these parameters at the design stage means that there is often a risk a trial may be under- or over-powered. For many study designs, this problem has been addressed by considering adaptive design methodology that allows for the re-estimation of the required sample size during a trial. Here, we propose and compare several approaches for this in multi-treatment crossover trials. Specifically, regulators favour re-estimation procedures to maintain the blinding of the treatment allocations. We therefore develop blinded estimators for the within and between person variances, following simple or block randomisation. We demonstrate that, provided an equal number of patients are allocated to sequences that are balanced for period, the proposed estimators following block randomisation are unbiased. We further provide a formula for the bias of the estimators following simple randomisation. The performance of these procedures, along with that of an unblinded approach, is then examined utilising three motivating examples, including one based on a recently completed four-treatment four-period crossover trial. Simulation results show that the performance of the proposed blinded procedures is in many cases similar to that of the unblinded approach, and thus they are an attractive alternative.

Summary

We haven't generated a summary for this paper yet.

Dice Question Streamline Icon: https://streamlinehq.com

Follow-up Questions

We haven't generated follow-up questions for this paper yet.